KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vir Biotechnology (VIR) EBT Margin (2018 - 2025)

Historic EBT Margin for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to 67905.42%.

  • Vir Biotechnology's EBT Margin fell 589331500.0% to 67905.42% in Q3 2025 from the same period last year, while for Sep 2025 it was 2961.95%, marking a year-over-year decrease of 22761200.0%. This contributed to the annual value of 704.95% for FY2024, which is 239900.0% up from last year.
  • Per Vir Biotechnology's latest filing, its EBT Margin stood at 67905.42% for Q3 2025, which was down 589331500.0% from 9125.86% recorded in Q2 2025.
  • Vir Biotechnology's 5-year EBT Margin high stood at 106.9% for Q3 2021, and its period low was 67905.42% during Q3 2025.
  • For the 5-year period, Vir Biotechnology's EBT Margin averaged around 6160.27%, with its median value being 719.35% (2023).
  • Per our database at Business Quant, Vir Biotechnology's EBT Margin soared by 86130100bps in 2022 and then crashed by -589331500bps in 2025.
  • Quarter analysis of 5 years shows Vir Biotechnology's EBT Margin stood at 67.17% in 2021, then plummeted by -557bps to 306.9% in 2022, then plummeted by -134bps to 719.35% in 2023, then dropped by -18bps to 845.93% in 2024, then tumbled by -7927bps to 67905.42% in 2025.
  • Its EBT Margin stands at 67905.42% for Q3 2025, versus 9125.86% for Q2 2025 and 3989.08% for Q1 2025.